1/17/12 ArQule Announces Tivantinib Meets Primary Endpoint, Significantly Extending Time to Progression in Phase 2 Trial in Second-Line Hepatocellular Carcinoma
12/6/11 ArQule, Inc. to Present at Oppenheimer 22nd Annual Healthcare Conference
